Zalicus
12
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
16.7%
2 terminated/withdrawn out of 12 trials
83.3%
-3.2% vs industry average
0%
0 trials in Phase 3/4
40%
4 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
A Study Comparing CRx-102 Plus Disease-modifying Anti-rheumatic Drug (DMARD) Therapy to Placebo Plus DMARD Therapy in RA
Role: lead
A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis
Role: lead
Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis
Role: lead
CRx-102 Osteoarthritis Multicenter Evaluation Trial
Role: lead
Phase 2 Efficacy Trial of Z160 in Lumbosacral Radiculopathy
Role: lead
Efficacy and Safety Study of Z160 in Subjects With Postherpetic Neuralgia
Role: lead
Long Term Safety Trial of z102 and Prednisone in Patients With Moderate to Severe Rheumatoid Arthritis
Role: lead
Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes
Role: lead
A Single-Center Exploratory Study to Assess the Activity of CRx-197-002 in Plaque Psoriasis
Role: lead
A Phase I Study to Assess the Safety and Tolerability of Topical CRx-197 Formulations in Healthy Volunteers
Role: lead
Study of CRx-191 to Assess Activity in Plaque Psoriasis
Role: lead
Phase I Study of Topical CRx-191 in Normal Healthy Volunteers
Role: lead
All 12 trials loaded